论文部分内容阅读
目的:研究热激蛋白47(heat shock protein 47,HSP47)在人脑胶质瘤组织中的表达情况及其临床意义。方法:收集2008年1月至2009年12月沈阳军区总医院神经外科收治并手术的92例胶质瘤患者的肿瘤组织和同期手术切除病理诊断为胶质细胞增生的非胶质瘤组织10例,另有15例冻存的胶质瘤组织(收集于2014年5月至2014年6月),应用免疫组织化学方法、Western blotting检测其中HSP47蛋白的表达部位及表达水平,并结合随访资料分析HSP47蛋白表达与临床病理指标、患者生存期之间的关系。结果:HSP47阳性主要定位于Ⅲ、Ⅳ级胶质瘤细胞胞质和血管内皮细胞,HSP47在胶质瘤组织中表达率为52.17%、在非胶质瘤组织中无表达,χ2检验非肿瘤组和胶质瘤组之间HSP47表达的差异有统计学意义(χ2=9.855,P=0.002)。不同年龄、性别胶质瘤患者间HSP47蛋白的表达差异无统计学意义(P=0.423,P=0.820);HSP47蛋白随着WHO病理级别增高阳性表达逐渐增多(P<0.05)。HSP47蛋白低表达组患者中位生存时间明显长于高表达组患者[43(95%CI,22.4~63.6)vs 17(95%CI,14.5~19.5)个月,P<0.01]。结论:HSP47在胶质瘤中过表达,并与病理级别呈正相关,高表达患者预后不良;HSP47可以作为胶质瘤诊断和治疗的新靶点。
Objective: To investigate the expression of heat shock protein 47 (HSP47) in human glioma tissue and its clinical significance. Methods: Tumor tissues from 92 patients with glioma admitted to Department of Neurosurgery, Shenyang Military Region General Hospital from January 2008 to December 2009 were collected, and 10 cases of non-glioma tissues with pathological diagnosis of glial proliferation were collected during the same period , And another 15 cases of frozen glioma tissues (collected from May 2014 to June 2014). Immunohistochemistry and Western blotting were used to detect the expression site and expression level of HSP47 protein. Combined with follow-up data analysis Relationship between HSP47 protein expression and clinicopathological parameters and patient survival. Results: The expression of HSP47 was mainly located in the cytoplasm and vascular endothelial cells of grade III and IV glioma cells. The expression rate of HSP47 in glioma tissue was 52.17%, but not in non-glioma tissue, and χ2 test in non-tumor group There was a significant difference in the expression of HSP47 between the glioma group and the glioma group (χ2 = 9.855, P = 0.002). There was no significant difference in the expression of HSP47 between different age and sex gliomas (P = 0.423, P = 0.820). The positive expression of HSP47 increased with the increase of WHO pathological grade (P <0.05). The median survival time was significantly longer in HSP47-overexpressing patients than in patients with high expression (43%; 95% CI, 22.4-63.6 vs 17%; 95% CI, 14.5-19.5 months, P <0.01). Conclusion: HSP47 is overexpressed in gliomas and positively correlated with the pathological grade. HSP47 can be used as a new target for the diagnosis and treatment of gliomas.